| Name |
CAS |
MF |
MW |
Single-letter sequence |
Three-letter sequence |
Number of AA |
Type |
Inquiry |
| PZ-128 (P1pal-7) |
371131-16-7 |
C55H99O9N13 |
1086.46 |
Palmitic acid–KKSRALF–NH2 |
Palmitic acid–Lys–Lys–Ser–Arg–Ala–Leu–Phe–NH2 |
7 |
Cell Penetrating Peptides |
|
| CMYIEALDKYAC |
|
C62H95N13O19S3 |
1422.69 |
H2N–CMYIEALDKYAC–OH |
H2N–Cys–Met–Tyr–Ile–Glu–Ala–Leu–Asp–Lys–Tyr–Ala–Cys–OH |
12 |
EGFR-targeting peptide |
|
| LS-7 |
|
C32H56N12O11 |
784.86 |
H2N–LQNAPRS–OH |
H2N–Leu–Gln–Asn–Ala–Pro–Arg–Ser–OH |
7 |
CD133 receptor–targeting peptide |
|
| PL2 |
|
C31H57N13O13 |
819.86 |
H2N–TSKQNSR–OH |
H2N–Thr–Ser–Lys–Gln–Asn–Ser–Arg–OH |
7 |
Fn-EDB- and NRP-1–targeting peptide |
|
| Met-pep1 |
|
C74H104N16O15 |
1457.72 |
H2N–YLFSVHWPPLKA–OH |
H2N–Tyr–Leu–Phe–Ser–Val–His–Trp–Pro–Pro–Leu–Lys–Ala–OH |
12 |
c-MET–targeting peptide |
|
| CPQPRPLC |
|
C38H64N12O10S2 |
913.12 |
H2N–CPQPRPLC–OH |
H2N–Cys–Pro–Gln–Pro–Arg–Pro–Leu–Cys–OH |
8 |
VEGFR-targeting peptide |
|
| PTP |
|
C36H64N8O10 |
768.94 |
H2N–KTLLPTP–OH |
H2N–Lys–Thr–Leu–Leu–Pro–Thr–Pro–OH |
7 |
Plectin-1–targeting peptide |
|
| TAASGVRSMH |
|
C40H69N15O14S1 |
1016.13 |
H2N–TAASGVRSMH–OH |
H2N–Thr–Ala–Ala–Ser–Gly–Val–Arg–Ser–Met–His–OH |
10 |
Pericyte-targeting peptide |
|
| LTLRWVGLMS |
|
C54H90N14O13S1 |
1175.44 |
H2N–LTLRWVGLMS–OH |
H2N–Leu–Thr–Leu–Arg–Trp–Val–Gly–Leu–Met–Ser–OH |
10 |
Pericyte-targeting peptide |
|
| WSGPGVWGASVK |
|
C58H83N15O15 |
1230.37 |
H2N–WSGPGVWGASVK–OH |
H2N–Trp–Ser–Gly–Pro–Gly–Val–Trp–Gly–Ala–Ser–Val–Lys–OH |
12 |
Ovarian cancer–targeting peptide |
|
| THRVHLH |
|
C39H62N16O9 |
— |
H2N–THRVHLH–OH |
H2N–Thr–His–Arg–Val–His–Leu–His–OH |
7 |
Human ovarian cancer cell–targeting peptide |
|
| CTLPHLKMC |
|
C44H74N12O11S3 |
1043.33 |
H2N–CTLPHLKMC–OH |
H2N–Cys–Thr–Leu–Pro–His–Leu–Lys–Met–Cys–OH |
9 |
Human B-cell lymphoma Raji cell–targeting peptide |
|
| HVGGSSV |
|
C26H43N9O10 |
641.67 |
H2N–HVGGSSV–OH |
H2N–His–Val–Gly–Gly–Ser–Ser–Val–OH |
7 |
TIP-1–targeting peptide |
|
| SSQPFWS |
|
C39H51N9O12 |
837.88 |
H2N–SSQPFWS–OH |
H2N–Ser–Ser–Gln–Pro–Phe–Trp–Ser–OH |
7 |
VAV3-targeting peptide |
|
| TMVP1446 |
|
C47H87N21O16S1 |
1234.39 |
H2N–CRRALGGGTTSR–OH |
H2N–Cys–Arg–Arg–Ala–Leu–Gly–Gly–Gly–Thr–Thr–Ser–Arg–OH |
12 |
VEGFR-3–targeting peptide |
|
| CSSRTMHHC |
|
C39H62N16O13S3 |
1059.2 |
H2N–CSSRTMHHC–OH |
H2N–Cys–Ser–Ser–Arg–Thr–Met–His–His–Cys–OH |
9 |
Melanoma-targeting peptide |
|
| AQYLNPS |
|
C35H53N9O12 |
791.85 |
H2N–AQYLNPS–OH |
H2N–Ala–Gln–Tyr–Leu–Asn–Pro–Ser–OH |
7 |
GSC–targeting peptide; |
|
| pHCT74 |
|
C57H101N15O17S2 |
1332.63 |
H2N–SSMDIVLRAPLM–OH |
H2N–Ser–Ser–Met–Asp–Ile–Val–Leu–Arg–Ala–Pro–Leu–Met–OH |
12 |
α-Enolase–targeting peptide |
|
| ALWPPNLHAWVP |
|
C70H97N17O14 |
1400.62 |
H2N–ALWPPNLHAWVP–OH |
H2N–Ala–Leu–Trp–Pro–Pro–Asn–Leu–His–Ala–Trp–Val–Pro–OH |
12 |
miR-21–targeting peptide |
|
| CPLHARLPC |
|
C43H70N14O10S2 |
1007.23 |
H2N–CPLHARLPC–OH |
H2N–Cys–Pro–Leu–His–Ala–Arg–Leu–Pro–Cys–OH |
9 |
Mycobacterium-targeting peptide |
|
